Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y.

J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):201-6.

2.

[Levodopa and cognitive disorders in Parkinson's disease].

Leiva-Santana C, Alvarez-Saúco M.

Rev Neurol. 2006 Jul 16-31;43(2):95-100. Review. Spanish.

3.

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.

Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV.

Brain. 1992 Dec;115 ( Pt 6):1701-25.

PMID:
1486457
4.

Which factors predict cognitive decline in Parkinson's disease?

Caparros-Lefebvre D, Pécheux N, Petit V, Duhamel A, Petit H.

J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):51-5.

5.

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.

Kulisevsky J, García-Sánchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estévez-González A.

Mov Disord. 2000 Jul;15(4):613-26.

PMID:
10928571
6.

Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test.

Pillon B, Dubois B, Bonnet AM, Esteguy M, Guimaraes J, Vigouret JM, Lhermitte F, Agid Y.

Neurology. 1989 Jun;39(6):762-8.

PMID:
2725868
7.
9.

[Cognitive dysfunction in patients with Parkinson's disease].

Zakharov VV, Iakhno NN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(1):13-9. Russian.

PMID:
15704477
10.

Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.

Bejjani BP, Gervais D, Arnulf I, Papadopoulos S, Demeret S, Bonnet AM, Cornu P, Damier P, Agid Y.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):595-600.

11.

Clinical predictive factors of subthalamic stimulation in Parkinson's disease.

Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y.

Brain. 2002 Mar;125(Pt 3):575-83.

12.

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.

Gotham AM, Brown RG, Marsden CD.

Brain. 1988 Apr;111 ( Pt 2):299-321.

PMID:
3378138
13.

Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.

Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A.

Mov Disord. 2008 May 15;23(7):998-1005. doi: 10.1002/mds.22007.

PMID:
18381647
14.

Dopamine and memory function in Parkinson's disease.

Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase TN.

Mov Disord. 1989;4(2):113-20.

PMID:
2543918
15.

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y.

Neurology. 1987 Sep;37(9):1539-42.

PMID:
3627454
16.

Dopaminergic effects on cognitive performance in patients with Parkinson's disease.

Lange KW, Paul GM, Naumann M, Gsell W.

J Neural Transm Suppl. 1995;46:423-32.

PMID:
8821078
17.

Cholinergic deficiency and frontal dysfunction in Parkinson's disease.

Dubois B, Pilon B, Lhermitte F, Agid Y.

Ann Neurol. 1990 Aug;28(2):117-21.

PMID:
2221841
18.

Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.

Stoffers D, Bosboom JL, Deijen JB, Wolters EC, Berendse HW, Stam CJ.

Brain. 2007 Jul;130(Pt 7):1847-60. Epub 2007 Apr 5.

19.

Dopamine and the regulation of cognition and attention.

Nieoullon A.

Prog Neurobiol. 2002 May;67(1):53-83. Review.

PMID:
12126656
20.

Slowing of reaction time in Parkinson's disease: the involvement of the frontal lobes.

Berry EL, Nicolson RI, Foster JK, Behrmann M, Sagar HJ.

Neuropsychologia. 1999 Jun;37(7):787-95.

PMID:
10408646
Items per page

Supplemental Content

Write to the Help Desk